Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
LINC01518 knockdown inhibits tumorigenicity by suppression of PIK3CA/Akt pathway in oesophageal squamous cell carcinoma.
|
31810385 |
2019 |
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
miR-145 sensitizes esophageal squamous cell carcinoma to cisplatin through directly inhibiting PI3K/AKT signaling pathway.
|
31582906 |
2019 |
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that ESCC cells harboring alterations in PI3K pathway were more resistant to radiation and combination of a clinical PI3Kα-selective inhibitor CYH33 and radiation synergistically inhibited cell proliferation in 14 ESCC cell lines.
|
31173854 |
2019 |
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Upregulated miR-30b-5p may inhibit migration and invasion in ESCC by targeting ITGA5, PDGFRB, and signaling pathways, such as PI3K/Akt, involved in ESCC regulation.
|
31463131 |
2019 |
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings showed that circVRK1 suppressed ESCC progression by regulating miR-624-3p/PTEN axis and PI3K/AKT signaling pathway, suggesting the potential therapeutic value of circVRK1 for ESCC.
|
30508543 |
2019 |
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Histone deacetylases inhibitor MS-275 suppresses human esophageal squamous cell carcinoma cell growth and progression via the PI3K/Akt/mTOR pathway.
|
31120582 |
2019 |
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of miR-133b could suppress proliferation, migration and invasion of ESCC cells by inhibiting MAPK/ERK and PI3K/AKT signaling pathways through targeting EGFR, indicating that miR-133b might be a potential therapeutic target for the treatment of ESCC.
|
30594787 |
2019 |
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Functional enrichment analyses provided important clues to investigate the biological functions for SRCR gene network in ESCC, such as extracellular structure organization and the PI3K-Akt signaling pathway.
|
31217847 |
2019 |
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, ALC1 knockdown inhibited glycolysis and inactivated the phosphatidylinositol 3-kinase (PI3K)/Akt pathway in ESCC cells.
|
31340168 |
2019 |
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> Summarily, this study indicated that LSD1 might positively regulate Notch and PI3K/Akt/mTOR pathways through binding the promoter regions of related genes in Notch pathway in ESCC.
|
31308693 |
2019 |
Squamous cell carcinoma of esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data indicated that components of the PI3K/AKT/mTOR pathway were overexpressed and activated in esophageal SCC.
|
31571914 |
2019 |
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, the results of the current study indicate that CACAN2D3 enhances the chemosensitivity of ESCC to cisplatin via inducing Ca<sup>2+</sup>-mediated apoptosis and suppressing PI3K/Akt pathways.
|
31001468 |
2019 |
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our data suggests that JNK inhibition in combination with anti-PI3K therapy is a new therapeutic strategy that should be tested in HPVPos and HPVNeg HNSCC and ESCC patients.
|
30860495 |
2019 |
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results provide rationale that combined inhibition of Rictor/mTORC2 and PI3K for the treatment of ESCC.
|
30119206 |
2018 |
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
The anti-tumor effects of dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A on inducing autophagy in esophageal squamous cell carcinoma.
|
29581778 |
2018 |
Squamous cell carcinoma of esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Osthole inhibits the PI3K/AKT signaling pathway via activation of PTEN and induces cell cycle arrest and apoptosis in esophageal squamous cell carcinoma.
|
29579711 |
2018 |
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further study elucidated that CEP55 facilitated ESCC via the PI3K/Akt pathway.
|
30050313 |
2018 |
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Long Non-Coding RNA (lncRNA) Growth Arrest Specific 5 (GAS5) Suppresses Esophageal Squamous Cell Carcinoma Cell Proliferation and Migration by Inactivating Phosphatidylinositol 3-kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
|
30368517 |
2018 |
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our study showed that ACY-1215 suppressed proliferation and promoted apoptosis in ESCC via miR-30d/PI3K/AKT/mTOR and ERK pathways and that ACY-1215 may be a promising antitumor agent in ESCC.
|
30050135 |
2018 |
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
MiR-214 promotes cell meastasis and inhibites apoptosis of esophageal squamous cell carcinoma via PI3K/AKT/mTOR signaling pathway.
|
29864623 |
2018 |
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Expression and Prognostic Impact of the PI3K/AKT/mTOR Signaling Pathway in Advanced Esophageal Squamous Cell Carcinoma.
|
29463194 |
2018 |
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, we inactivated the PI3K pathway in ESCC cell lines with the PI3K inhibitor LY294002 and then detected STMN1 expression by western blot analysis.
|
29251330 |
2018 |
Squamous cell carcinoma of esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Compared with normal tissues, the level of miR-1 expression was significantly lower and PIK3CA expression was higher in ESCC tissues.
|
29399158 |
2018 |
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we report that miR-141-3p suppress the expression of PHLPP2, a negative regulators of the AKT/PI3K pathway, as a target in ESCC.
|
29738771 |
2018 |
Squamous cell carcinoma of esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lobaplatin promotes radiosensitivity, induces apoptosis, attenuates cancer stemness and inhibits proliferation through PI3K/AKT pathway in esophageal squamous cell carcinoma.
|
29597090 |
2018 |